Clinical trial NCT02902029: Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Official title: A Phase II, Open-label, Randomized-controlled Trial Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody Atezolizumab for the Treatment in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Malignant Melanoma
Keywords: unresectable stage IIIB, IIIC, IV melanoma
Lead sponsor: University Hospital, Essen
Sponsor class: OTHER
First posted: 2016-09-15
Enrollment: 186
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Most patients with locally advanced or metastatic tumors succumb to their disease. Thus, there is a substantial need for novel therapeutic strategies to improve the outcome for patients with advanced or metastatic melanoma. Targeting the the Ras/Raf signalling pathway by BRAF and MEK inhibition as well as targeting immunologic checkpoint control with an antiPD-L1 antibody have emerged as treatment option.

In this study the best timing for sequential use of both treatment options (BRAF/MEK inhibition and antiPD-L1 antibody) in patients with unresectable or metastatic BRAFV600 mutant melanoma will be assessed.

Detailed description: At this time there is no experience concerning the sequencing strategy when using the two effective therapeutical approaches as targeting the Ras/Raf signalling pathway by BRAF and MEK inhibition or targeting immunologic checkpoint control with an antiPD-L1 antibody.

This is a prospective, open, multicenter, randomized phase II study in patients with unresectable or metastatic BRAFV600 mutant melanoma. In this study the scheduling of the treatment with a combined BRAF/MEK inhibition and the treatment with an anti-PD-L1 antibody will be assessed.

After a 3 months run-in period with vemurafenib and cobimetinib, all patients who did not show disease progression or treatment interruption for more than 28 days during run-in phase will be randomized in a 1:1 ratio:

* either to proceed vemurafenib and cobimetinib until disease progression and subsequently cross-over to atezolizumab treatment until disease progression (Arm A).
* or to receive the anti-PD-L1 antibody atezolizumab until disease progression and subsequently cross-back to vemurafenib and cobimetinib until disease progression (Arm B). In a translational research program tumor tissue, blood plasma and peripheral blood mononuclear cell will be analyzed to evaluate the biologic effects of treatment sequence on the molecular profile and biomarker expression in tissue and plasma.

Eligibility criteria: Inclusion Criteria:

* Be willing and able to provide written informed consent for the trial.
* Male or female patient being ≥18 years of age on day of signing informed consent.
* Histologically confirmed diagnosis of locally advanced, unresectable or metastatic melanoma AJCC (unresectable stage IIIB, IIIC, IVM1a, IVM1b, or IVM1c) without active or untreated brain metastases; all known CNS lesions must have been treated with stereotactic therapy or surgery at least 4 weeks prior to the first dose of trial treatment AND the patient must be without evidence of clinical or radiographic disease progression in the CNS for at least 4 weeks prior to the first dose of trial treatment and any neurologic symptoms must have returned to baseline, the patient must have no evidence of new or enlarging brain metastases, and the patient must not have used steroids for at least 3 weeks prior to trial treatment.
* No previous therapy for the advanced or metastatic stage. Prior adjuvant therapy is permitted (e.g. Interferon, Interleukin-2-therapy, chemo- or radiotherapy). Prior adjuvant therapy has to be terminated (last dose) at least 28 days before enrolment. Patients who are in follow-up period of a clinical trial in adjuvant setting and progressing may be enrolled / randomized.
* Measurable disease, i.e., present with at least one measurable lesion per RECIST, version 1.1, for the definition of a measureable lesion.
* Presence of BRAF mutation (V600) in tumor tissue.
* Performance status of 0 or 1 on the ECOG Performance Scale.
* Adequate organ function.
* Adequate cardiac function.
* Able to take oral medications.
* Female subject of childbearing potential should have a negative pregnancy test within 72 hours prior to receiving the first dose of study medication.
* Female patients of childbearing potential and male patients with partners of childbearing potential must agree to always use a highly effective form of contraception according to CTFG during the course of this study and for at least 6 months after completion of study therapy.

Exclusion Criteria:

* Use of any investigational or non-registered product within the 30 days before registration.
* Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to study Day 1.
* Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-Cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) antibody (including ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways).
* Prior therapy with a BRAF inhibitor (including but not limited to vemurafenib, dabrafenib, encorafenib and / or MEK inhibitor
* Prior major surgery.
* Known additional malignancy that is progressing or requires active treatment within 5 years prior to the study.
* Known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
* History of leptomeningeal metastases.
* History or current evidence of central serous retinopathy (CSR) or retinal vein occlusion (RVO) or predisposing factors to RVO or CSR.
* History of retinal degenerative disease.
* History of allogenic bone marrow transplantation or organ transplantation.
* History of Gilbert's syndrome.
* Impaired cardiovascular function or clinically significant cardiovascular diseases.
* Uncontrolled arterial hypertension despite medical treatment.
* Impairment of gastrointestinal function or gastrointestinal disease.
* Evidence of interstitial lung disease or active, non-infectious pneumonitis.
* Active infection requiring systemic therapy.
* Positive test for Human Immunodeficiency Virus (HIV).
* Positive test for Hepatitis B or Hepatitis C.
* Known hypersensitivity reaction to any of the components of study treatment.
* Medical, psychiatric, cognitive or other conditions, including known alcohol or drug abuse.
* Patients having received a live, attenuated vaccine within 4 weeks prior to the first dose of trial treatment.
* Legal incapacity or limited legal capacity.

Primary outcomes:
measure: Time to First Documented Disease Progression
timeFrame: 4 years
Secondary outcomes:
measure: Time to Second Objective Disease Progression (PFS2)
timeFrame: 4 years
measure: Adverse events according to CTCAE Version 4.03 criteria (Safety / Toxicity)
timeFrame: Until 90 days of discontinuation of dosing of the investigational product
measure: Overall survival
timeFrame: 4 years
measure: Overall survival 12 months
timeFrame: 1 year
measure: Overall survival 24 months
timeFrame: 2 years
measure: Overall survival 36 months
timeFrame: 3 years
measure: Overall survival 48 months
timeFrame: 4 years
measure: 12-months disease control rate (DCR)
timeFrame: 1 year
measure: 24-months disease control rate (DCR).
timeFrame: 2 years
measure: Rate of patients with progressive disease who could not cross-over to subsequent line of therapy due to deterioration of ECOG status or multiple and/or symptomatic brain metastases and/or leptomengial disease
timeFrame: 4 years
measure: Time from first documented tumor progression until second documented tumor progression
timeFrame: 4 years
Other outcomes:
Locations:
city: Boulogne-Billancourt
country: France
facility: Hôpital Ambroise-Paré
city: Lille
country: France
facility: Hospital Claude Huriez
city: Marseille
country: France
facility: Hôpital de la Timone
city: Nantes
country: France
facility: CHU de Nantes
city: Pierre-Bénite
country: France
facility: Centre Hospitalier Lyon Sud
city: Heilbronn
country: Germany
facility: SLK-Kliniken Heilbronn GmbH
state: Baden-Wuerttemberg
city: Mannheim
country: Germany
facility: University Hospital Mannheim, Clinic for Dermatology
state: Baden-Wuerttemberg
city: Heidelberg
country: Germany
facility: National Centre for Tumour Diseases (NCT)
state: BW
city: Essen
country: Germany
facility: University Hospital Essen, Department of Dermatology, Skin Cancer Center
state: North Rhine-Westphalia
city: Erfurt
country: Germany
facility: HELIOS Klinikum Erfurt
state: Thuringia
city: Berlin
country: Germany
facility: Charité-Universitätsmedizin Berlin
city: Buxtehude
country: Germany
facility: Elbe Kliniken Stade - Buxtehude
city: Dresden
country: Germany
facility: Universitätsklinik Dresden
city: Hannover
country: Germany
facility: Medizinische Hochschule Hannover
city: Homburg/Saar
country: Germany
facility: Universitätsklinikum des Saarlandes
city: Kiel
country: Germany
facility: Universitäts-Hautklinik Kiel
city: Köln
country: Germany
facility: Universitätsklinikum Köln
city: Leipzig
country: Germany
facility: Universitätsklinikum Leipzig
city: Ludwigshafen
country: Germany
facility: Gesellschaft für Klinische Forschung Ludwigshafen mbH
city: Lübeck
country: Germany
facility: Universitätsklinikum Schleswig-Holstein
city: Mainz
country: Germany
facility: Universitätsklinikum Mainz
city: Minden
country: Germany
facility: Johannes Wesling Klinikum Minden
city: München
country: Germany
facility: Klinikum der Universität München
city: Tübingen
country: Germany
facility: Universitätsklinikum Tübingen
city: Würzburg
country: Germany
facility: Uniklinikum Würzburg
city: Athens
country: Greece
facility: &#34;LAIKO&#34; General Hospital of Athens
city: Belgrad
country: Serbia
facility: Military Medical Academy
Study officials:
affiliation: University Hospital, Essen
name: Dirk Schadendorf, Prof. Dr.
role: PRINCIPAL_INVESTIGATOR
References: